VRTX34 Stock Overview
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF).
Snowflake Score | |
---|---|
Valuation | 3/6 |
Future Growth | 3/6 |
Past Performance | 6/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for VRTX34 from our risk checks.
Vertex Pharmaceuticals Incorporated Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$553.79 |
52 Week High | US$554.04 |
52 Week Low | US$360.10 |
Beta | 0.39 |
1 Month Change | 9.79% |
3 Month Change | 5.44% |
1 Year Change | 29.78% |
3 Year Change | 94.46% |
5 Year Change | 225.06% |
Change since IPO | 225.06% |
Recent News & Updates
Recent updates
Shareholder Returns
VRTX34 | BR Biotechs | BR Market | |
---|---|---|---|
7D | 8.7% | -0.3% | -0.6% |
1Y | 29.8% | -2.2% | 9.7% |
Return vs Industry: VRTX34 exceeded the BR Biotechs industry which returned -2.1% over the past year.
Return vs Market: VRTX34 exceeded the BR Market which returned 10.3% over the past year.
Price Volatility
VRTX34 volatility | |
---|---|
VRTX34 Average Weekly Movement | 3.1% |
Biotechs Industry Average Movement | 9.2% |
Market Average Movement | 4.8% |
10% most volatile stocks in BR Market | 9.0% |
10% least volatile stocks in BR Market | 2.2% |
Stable Share Price: VRTX34 has not had significant price volatility in the past 3 months.
Volatility Over Time: VRTX34's weekly volatility (3%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1989 | 5,400 | Reshma Kewalramani | www.vrtx.com |
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company’s pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial.
Vertex Pharmaceuticals Incorporated Fundamentals Summary
VRTX34 fundamental statistics | |
---|---|
Market cap | R$571.48b |
Earnings (TTM) | R$20.70b |
Revenue (TTM) | R$52.46b |
27.6x
P/E Ratio10.9x
P/S RatioIs VRTX34 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
VRTX34 income statement (TTM) | |
---|---|
Revenue | US$10.19b |
Cost of Revenue | US$4.55b |
Gross Profit | US$5.64b |
Other Expenses | US$1.62b |
Earnings | US$4.02b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | 15.58 |
Gross Margin | 55.35% |
Net Profit Margin | 39.46% |
Debt/Equity Ratio | 0% |
How did VRTX34 perform over the long term?
See historical performance and comparison